peptides for female infertility FAQ

Discard it immediately. Lyophilised peptides should reconstitute into a clear, colourless solution. Cloudiness indicates protein aggregation or contamination—both render the compound biologically inactive and potentially immunogenic. This most commonly occurs when bacteriostatic water is stored improperly or when the lyophilised powder was exposed to humidity before reconstitution. Never inject cloudy peptide solutions—the risk of injection site reaction or systemic immune response outweighs any potential benefit.

Check the cycle day of administration—kisspeptin only triggers ovulation when a dominant follicle is already present (typically cycle day 12–14 in a 28-day cycle). Administering it during the early follicular phase (days 3–8) won't work because no mature follicle exists to respond to the LH surge. Ultrasound monitoring to confirm follicle size (≥18mm) before injection is essential. If follicle development is absent despite FSH priming, the issue is ovarian response—not hypothalamic signalling—and peptide therapy won't resolve it.

Yes, but timing matters. Progesterone supplementation typically begins 1–3 days post-ovulation to support luteal phase endometrial thickening. Follistatin should be administered starting on cycle day 21 (mid-luteal phase) to coincide with the implantation window. The two don't interact pharmacologically, but both require subcutaneous or intramuscular injection—patients should rotate injection sites to prevent lipohypertrophy. Combining them into a single syringe is not recommended unless both are formulated in identical carrier solutions.

Administer the missed dose as soon as you remember if fewer than 48 hours have passed. If more than 48 hours have elapsed, skip the missed dose and resume your regular schedule. Tβ4's mechanism (Treg upregulation) builds cumulatively over weeks—missing a single dose doesn't erase prior progress, but missing multiple doses reduces therapeutic plasma levels below the threshold needed to suppress uNK cell activity. Consistency matters more than perfection.

Cloudiness indicates aggregation or contamination. Both render the peptide unsafe and ineffective. Properly reconstituted peptides should be clear and colorless. Cloudiness can result from improper mixing (shaking instead of gentle swirling), incorrect diluent (using sterile water instead of bacteriostatic water for multi-dose vials), or bacterial contamination from non-sterile technique. Discard the vial immediately and reconstitute a fresh dose following aseptic protocol. Using a cloudy solution risks injection site infection and zero therapeutic effect.

Kisspeptin has a 30-minute half-life, and the LH surge it triggers peaks 10–14 hours post-injection. Missing the 34–36 hour pre-ovulation window means the surge occurs too early or too late relative to follicular maturity. If you miss the scheduled dose by more than 4 hours, contact your reproductive endocrinologist before proceeding. Administering late may result in ovulation of an immature oocyte or premature luteinization, both of which reduce fertilization probability. Do not double-dose to compensate.

Follistatin may improve follicle recruitment if your AMH is below 1.0 ng/mL and standard FSH protocols yield fewer than 5 oocytes per cycle. The mechanism. Activin neutralization. Enhances granulosa cell responsiveness to FSH, potentially increasing antral follicle count by 18–22% based on early-phase trials. This is not egg quality improvement. It's recruitment optimization. If your ovarian reserve is severely depleted (AMH below 0.3 ng/mL), even enhanced FSH sensitivity cannot recruit follicles that no longer exist.